# ATLANTIS JAPAN GROWTH FUND



CUMULATIVE PERFORMANCE % (£)	YTD	1M	3M	1Y	3Y	5Y	2019	2018	2017	2016	2015	ITD*
AJG Share Price	-1.09	-1.09	1.11	19.74	50.91	78.08	24.32	-15.53	51.56	3.96	17.30	238.26
AJG Share NAV	-5.37	-5.37	-0.99	17.21	48.19	78.97	32.39	-14.97	42.94	8.61	15.94	286.63
Topix TR Index	-2.52	-2.52	-0.65	9.73	17.71	64.39	16.05	-8.85	15.63	24.47	16.92	62.55

Sources: Northern Trust and Bloomberg


Notes: \* Inception to date NAV return figure was converted to GBP based on the official USD NAV using Bloomberg FX rate

### **NEW DIVIDEND POLICY**

At the 2019 AGM, shareholders approved the Board's recommendation to replace the redemption facility with a regular dividend paid to all shareholders on a quarterly basis set at 1% of net asset value at the close of the preceding financial year.

The quarterly dividend will be paid out of capital resources at the end of each calendar quarter. The current dividend rate for quarterly payments through to June 2020 is 2.37p per share, being 1% of the average daily NAV per share in the final month of the Company's financial year ended 30 April 2019.

# PERFORMANCE OVER 5 YEARS (£)



Sources: Northern Trust and Bloomberg.

Notes: The figures in the above table and chart refer to past performance which is not a reliable indicator of future results. An investment in the Fund would place an investor's capital at risk. Figures shown are net of all fees

# **MANAGER'S COMMENTARY**

The Japanese equity market began the year by setting aside Middle East geopolitical concerns and focused on the positive by welcoming, with a rally, the China-U.S. trade agreement. However, this feel-good sentiment quickly crumbled when the world learned of a new, deadly coronavirus spreading in Wuhan, China. Information regarding the extent of the virus' diffusion was lacking and the market was left on its own to determine the potential impact on Chinese and global supply chains. As we write, despite aggressive lock-downs imposed by the authorities, the virus has yet to be brought under control. In response to this, Japanese equity investors took the market lower, particularly 'in-bound' stocks (cosmetics, hotels, air transportation). Lost in the virus concern has been the release of 3Q FY3/20 results which can, at best, be considered mixed.

Given this backdrop, for January in GBP and on a total return basis, Atlantis Japan Growth Fund retreated 5.37%. This performance lagged the TOPIX and Nikkei 225 indices which declined 2.52% and 2.29% respectively. The Fund's performance also failed to keep pace with the TSE-2 Index (-2.94%) and the Nikkei OTC Average (-1.53%). The risk-off mood was most apparent with TSE Mothers, which dropped over 8% in January.

The stocks making positive contributions to the Fund's performance over the course of the month included Tri-Chemical Laboratories (4369), a supplier of ultrapure chemicals to semiconductor wafer makers; Renova (9519), a renewable energy generator; management consultant Funai Soken (9757); and consumer financer Aiful (8515). Stocks that detracted from the

### **KEY FACTS**

### **INVESTMENT OBJECTIVE**

Aims to achieve long-term capital growth through investment wholly or mainly in listed Japanese equities.

#### FUND INFORMATION

Lead portfolio adviser	Taeko Setaishi
Lead adviser start date	1 <sup>st</sup> May 2016
Total Net Assets (TNA)	GBP 105m
Shares in issue	41,794,570
Share price	227.5p
NAV per share	251.9p
Discount(-)/Premium	-9.7%
Net gearing	3.2%
Active Share	96.4%
Inception date	10 <sup>th</sup> May 1996

### **ADMINISTRATIVE & DEALING INFORMATION**

ADMINISTRATIVE & DEALING INFORMATION				
Financial Year End	30 <sup>th</sup> April			
Company Domicile	Guernsey			
Company Legal Structure	UK Investment Trust			
Listing	London Stock Exchange			
Valuation	Daily			
Company Broker	Cantor Fitzgerald			
Depositary	Northern Trust			
Administrator	Northern Trust			
Auditor	PricewaterhouseCoopers			
Investment Manager	Quaero Capital LLP			
Investment Adviser	Atlantis Investment Research Corporation			

### DIVIDEND

Prospective dividend yield\* 4.2%
Dividends paid March, June,
September and

December

# **COMPANY FEES & EXPENSES**

Ongoing Charges\*\* 1.63%

Annual Management Fee 1.00% up to £125m

0.85% between £125m-£175m

0.70% greater than £175m

### **FUND CODES**

 Bloomberg
 AJG LN

 SEDOL
 B61ND55

 ISIN
 GG00B61ND550

<sup>\*</sup> Annualised dividend yield based on indicated dividend payments in respect of the two quarters ending 31 March 2020 and 30 June 2020. Not a profit forecast.

<sup>\*\*</sup> Based on the Company's Annual Financial Statements to 30 April 2019.

performance were Bengo4 (6027), TKP (3479), Recruit Holdings (6098), and Nihon M&A (2127).

At the end of January the Company's portfolio held 61 stocks, a net reduction of one over the course of the month. Ceramic parts maker Maruwa (5344) was added to the portfolio while Bplats (4381) and Riso Kyoiku (4714) were sold.

Investor data for January indicate non-resident investors were marginal net sellers of equities on a cash basis (JPY 42bn) but massive sellers of futures (JPY 753bn). Over the course of the month individual investors were net buyers, as were non-financial business corporations. Both investment trusts and trusts banks were net sellers. Calendar year to date the BoJ's ETF purchases have been a modest JPY 210bn, well below the JPY 600bn targeted monthly run rate. The average daily trading value on the TSE was JPY 2.09tn, an improvement over December's holiday shortened JPY 1.87tn.

The market's January retreat encompassed 28 out of the TSE's 33 sectors. Investors fled from sectors whose earnings were perceived to be at risk from the coronavirus outbreak. As a consequence, the worst performing sectors were marine transportation, mining, air transportation, non-ferrous metals, and oil & coal. Investors swung behind sectors that could be characterized as non-cyclical, domestics, namely real estate, other financials, securities and commodities futures. Pharmaceuticals and precision instruments (home of medical device assemblers) were also bid for. Large capitalized growth stocks were generally in favour while small capitalized stocks, either growth or value, were notably ignored.

The Fund's net gearing at the end of January was 3.2%. Excluding cash, the Fund was

entirely invested in equities of publicly listed Japanese companies and J-REITs. The Fund had no exposure to any structured financial product, nor did it have any currency hedges in place during the month. At the end of January, the JPY rate against the GBP was 143.25, a loss of 0.39% from December's 142.69 close.

Coincident economic data and survey results, gathered prior to the virus outbreak, presented the picture of an economy adjusting to a series of one-off shocks (typhoons, sales tax hike, trade friction/boycotts). Without knowing when the virus will be brought under control estimates regarding its impact on the economy are guestimates at best. At present, consensus estimates assume the virus will come under control by mid-2020 which would result in Japanese GDP shrinking by 0.5% in the January-March quarter. Subsequent quarters should see the release of virus induced pent-up demand combined with the introduction of a JPY 26tn supplementary budget; these will limit the economic contraction in CY 2020 to 0.1%. On these estimates the Tokyo market is currently priced on a 15.6x forward PER and a 1.3x PBR while yielding at 2.1%. If it takes longer to contain the epidemic these projections will prove to be overly optimistic.

The Investment Adviser is of the view that the sell-off sparked by the virus will have no lasting negative impact on Japan's economy. It further believes that in retrospect this could represent an opportunity to acquire attractive equities with long term growth potential and remains committed to a growth oriented, bottom-up, stock-picking investment style with investment decisions based on proprietary fundamental research. The objective is to identify attractively priced, long term investment opportunities particularly in, but not limited to, technology, health care, and services.

# **PORTFOLIO STATISTICS**

MARKET EXPOSURE	103.2%		
TOP 10 HOLDINGS	(% TNA)		
Lasertec	5.1		
Hikari Tsushin	3.6		
Tri Chemical Laboratories	3.5		
S-Pool	3.2		
Tokyo Electron	3.1		
Nidec	3.1		
Asahi Intecc	3.1		
Keyence	3.0		
Nittoku Co	2.8		
Nihon M&A Center	2.6		

SECTOR BREAKDOWN	(% TNA)
Consumer Discretionary	11.7
Financials	1.1
Health Care	10.8
Industrials	42.8
Information Technology	22.7
Materials	1.5
Real Estate	6.7
Communication Services	4.2
Utilities	1.7

MARKET CAPITALISATION	(% TNA)
> 10bn	13.1
5-10bn	11.2
2-5bn	14.1
0.5-2bn	29.1
< 0.5bn	35.7

## **CONTACTS**

### **INVESTOR RELATIONS**

Contact: Richard Gittus
Phone: +44 (0)20 7747 5778
Email: InvestorServices.uk@quaerocapital.com

### FUND BROKER

Contact: Richard Harris
Phone: +44 (0)20 7894 8229
Email: richard.harris@cantor.com

## **KEY RISKS**

- Past performance is not a reliable indicator of future results. The value of your investment may go down as well as up and you may not get back the amount originally invested.
- » The Fund may be invested in securities denominated in currencies other than Sterling. Changes in exchange rates may cause your investment to decrease or increase in value.
- » The Fund, as an investment trust, is a public limited company, the shares of which are traded on the London Stock Exchange. Investment trusts are not authorised and regulated by the Financial Conduct Authority.
- » Investment trusts may borrow money in order to make further investments. This is known as 'gearing' or 'leverage'. The effect of gearing can enhance returns to shareholders in rising markets but will have the opposite effect on returns in falling markets.
- The Fund may invest in smaller companies which are generally considered to carry a higher degree of risk as the market for their shares is often less liquid than that for larger companies.
- » An investment trust's exposure to a single market and currency may increase the level of risk.

### IMPORTANT INFORMATION

This newsletter is prepared on behalf of Atlantis Japan Growth Fund Limited (the "Fund") by Quaero Capital LLP ("Quaero"), which is authorised and regulated by the United Kingdom Financial Conduct Authority ("FCA") with registered number 434203. Quaero is registered in England & Wales under number OC314014 and has its registered office at 2-4 King Street, London SW1Y 6QL. This newsletter does not constitute an offer of or solicitation to buy shares in the Fund ("Shares"). The key information document ("KID") contains detailed information on risk factors and fees that may apply and should be read carefully before investing. No investment decisions should be made without first reviewing the KID (available in English) for the Fund which can be obtained from www.quaerocapital.uk or requested directly from Quaero via email at InvestorServices.uk@quaerocapital.com or by calling us on +44 (0)20 7747 5770.

This newsletter is being communicated by Quaero only to persons who qualify as (a) eligible counterparties, (b) professional customers or (c) exempted recipients under any of the exemptions to section 21 of the United Kingdom Financial Services and Markets Act 2000 (FSMA). Investors in the Fund will be shareholders in the Fund and not customers of Quaero. As such they are advised that in respect of an investment in the Fund they will not generally benefit from the protection of FSMA and provisions made thereunder or the United Kingdom Financial Services Compensation Scheme and will not have access to the United Kingdom Financial Ombudsman Services in the event of a dispute. Past performance is not necessarily a guide to the future performance. The value of Shares in the Fund and the income derived from them may go down as well as up. Changes in rates of exchange may be one of the causes of the value of investment in the Fund to go up and down. This newsletter is written for the benefit of the category of persons described above. It is not addressed to any other person and may not be used by them for any purpose whatsoever. It expresses no views as to the suitability of the investments described herein to the individual circumstances of any recipient.

Copyright Quaero Capital LLP 2020. All rights reserved.